BioVie (BIVI) director receives 57,500 stock options with 2026 vesting

Rhea-AI Filing Summary

BioVie Inc. director Kameel D. Farag received a grant of 57,500 stock options on January 5, 2026. The options have an exercise price of $1.31 per share and, if not exercised, expire on January 5, 2031. Each option is exercisable for one share of BioVie common stock, giving Farag the right to buy up to 57,500 shares.

According to the vesting terms, 7,500 options vest on the grant date, while the remaining options vest in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the company’s 2026 annual shareholders’ meeting. After this grant, Farag beneficially holds 57,500 derivative securities in the form of these stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farag Kameel D.

(Last) (First) (Middle)

C/O BIOVIE INC.

680 W NYE LANE STE. 201

(Street)

CARSON CITY NV 89703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOVIE INC. [ BIVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.31	01/05/2026		A		57,500		(1)	01/05/2031	COMMON STOCK	57,500	$0	57,500	D

Explanation of Responses:

1. 7,500 shares of the underlying options vest s on grant date and the remaining balance in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026 and the earlier of November 11, 2026 and the date of the registrant's 2026 annual shareholders' meeting.

	/s/ Joanne Wendy Kim, attorney-in-fact for Kameel Farag	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BioVie (BIVI) report in this Form 4?

BioVie reported that director Kameel D. Farag was granted 57,500 stock options on January 5, 2026, giving him the right to buy BioVie common stock.

What is the exercise price and expiry of Kameel Farag’s BioVie stock options?

The stock options have an exercise price of $1.31 per share and an expiration date of January 5, 2031, if they are not exercised earlier.

How do the 57,500 BioVie (BIVI) stock options granted to Kameel Farag vest?

7,500 options vest on the grant date, and the remaining balance vests in four equal installments on February 11, 2026, May 11, 2026, August 11, 2026, and the earlier of November 11, 2026 and the 2026 annual shareholders’ meeting.

How many BioVie derivative securities does Kameel Farag hold after this transaction?

After the reported grant, Kameel D. Farag beneficially owns 57,500 derivative securities, all in the form of stock options on BioVie common stock.

Is Kameel D. Farag a director or officer of BioVie (BIVI)?

Yes. The filing identifies Kameel D. Farag as a director of BioVie Inc. and notes that the Form 4 is filed for one reporting person.